menu
    • menu
    [{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Phase III","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel","graph1":"Neurology","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for (+-)-Bupivacaine hydrochloride

    Menu

    (+-)-Bupivacaine hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MedinCell

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            MedinCell

                            France arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib,Bupivacaine Hydrochloride,Paracetamol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MedinCell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (mdc-CWM), a First...

                            Details : F14 (celecoxib) is a sustained-release formulation of the non-steroidal anti-inflammatory drug (NSAID), celecoxib, administered into the intra-articular space at the end of TKR surgery.

                            Brand Name : F14 (mdc-CWM)

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2023

                            Lead Product(s) : Celecoxib,Bupivacaine Hydrochloride,Paracetamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Acasti Pharma

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Acasti Pharma

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharma...

                            Details : GTX-101 is a novel formulation of bupivacaine hydrochloride for topical administration via a bio-adhesive, film-forming polymer, for relief of pain associated with Postherpetic Neuralgia, a neuropathic pain caused by nerve damage from the varicella zoste...

                            Brand Name : GTX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 22, 2022

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Acasti Pharma

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Acasti Pharma

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for th...

                            Details : GTX-101 (bupivacaine hydrochloride) topical administration via bio-adhesive, film-forming polymer, for relief of pain associated with PHN, a persistent and often debilitating neuropathic pain caused by nerve damage from shingles, which may persist for mo...

                            Brand Name : GTX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 27, 2022

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocoll Announces Positive Topline Results For XARACOLL® (bupivacaine hydrochloride) Implant in a Phase 3 St...

                            Details : XARACOLL (Bupivacaine HCl), an innovative collagen drug-device implant, 300mg dose cohort experienced less pain and, was generally well tolerated with an adverse event profile comparable to the current prescribing information.

                            Brand Name : Xaracoll

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 02, 2022

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI) Implant

                            Details : Approved by the US Food and Drug Administration (FDA) in August 2020, XARACOLL is a unique, non-injectable, drug-device combination in the form of a fully bioresorbable collagen implant containing bupivacaine hydrochloride.

                            Brand Name : Xaracoll

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 29, 2020

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves XARACOLL® (bupivacaine HCl) Implant

                            Details : US Food and Drug Administration (FDA) has approved Xaracoll® for acute postsurgical pain relief for up to 24 hours in adults following open inguinal hernia repair, a painful and commonly-performed surgery.

                            Brand Name : Xaracoll

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2020

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL

                            Details : If approved, XARACOLL will be Innocoll's first commercially available product in the US.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 26, 2020

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Innocoll Pharmaceuticals Limited

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL

                            Details : Innocoll anticipates a 6-month review by the FDA.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 27, 2020

                            Lead Product(s) : Bupivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth